Alcohol Use Disorder (Nursing)

Sara Nehring; Richard Chen; Andrew Freeman

Alcohol Use Disorder (Nursing)

Learning Outcome

Complications of alcohol use disorders can be far-reaching and can impact a patient's socioeconomic status, mental health, interpersonal relationships, employment, and physical well-being.
Early intervention and repeated non-malignant discussions between the patient and provider are important.
The patient's successes should be noted and resources for continued efforts offered at each visit.
Discussion regarding barriers to the patient seeking cessation or assistance should occur to find new ways to approach the alcohol use disorder (AUD) in the hope of improving successful cessation of the behaviors.

Introduction

Alcohol misuse has been linked to numerous social, economic, and health problems. Estimates vary but have suggested that up to 40% of patients have experienced complications of alcohol misuse. In the United States, 138.3 million people age 12 and older, surveyed, report that they actively use alcohol, according to the 2015 National Survey on Drug Use and Health. Of those, 48.2% report that they had binge drinking episode(s) within 30 days before taking the survey. Of those who reported binge drinking, 26% reported heavy alcohol use, defined as binge drinking five or more days in the previous 30 days, which accounts for 12.5% of total alcohol users. This means that 5.9%, or 15.7 million people in the United States aged 12 and older, meet criteria for an alcohol use disorder (see image for criteria). More than 85,000 deaths per year can be attributed to alcohol.[1][2][3]

Nursing Diagnosis

Alcohol abuse
Poor nutrition
Mental health issues
Poor performance at work and in academics

Causes

Although the pathogenesis of alcohol use disorder is not strictly known, several factors are thought to contribute to its development. These include environmental influences, such as home environments, peer interactions, genetic factors, the level of cognitive functioning, and certain existing personality disorders. Some of the genes suspected include GABRG2 and GABRA2, COMT Val 158Met, DRD2 Taq1A, and KIAA0040. Personality disorders associated with the development of an alcohol use disorder include disinhibition and impulsivity-type disorders, as well as depressive and socialization-related disorders.[4]

Risk Factors

According to the 2015 National Survey on Drug Use and Health conducted by the Substance Abuse and Mental Health Administration, an estimated 20.8 million Americans age 12 and older had a substance use disorder, of which 15.7 million were alcohol use disorders. Of those, 2.7 million had an illicit drug use disorder as well. This number makes alcohol the leading substance abused in the United States. Of the people with alcohol use disorder and illicit drug disorder, 623,000 of these were adolescents ages 12 to 17 (2.5% of all adolescents). Almost four million (3.8 million) individuals ages 18-25 (10.9% of young adults) and 11.3 million individuals 26 years or older (5.4%) had both an alcohol use disorder and illicit drug disorder. However, this number has been steadily declining since 2002. Almost half of the people with any substance abuse problem, including alcohol, also had a co-existing mental illness.[5][6][7]

Assessment

History gathering will often reveal reported episodes of binge drinking of four or five or more drinks at a time. Use of CAGE questionnaire will reveal a score of 2 or greater (CAGE means (1) have you ever felt you should Cut down on your drinking, (2) have you ever been Annoyed by people criticizing your drinking, (3) have you ever felt Guilty about your alcohol use, or (4) have you ever needed an Eye-opener to steady your nerves or get rid of a hangover). The patient may also report frequent falls, blackout spells, unsteadiness, or visual disturbances. They may report seizures if they went a few days without drinking, or tremors, confusion, emotional disturbances, and frequent job changes. They may also report social issues, such as job termination, separation/divorce, estrangement from family, of loss of their home. They may also report sleep disturbances.

The patient may have hypertension (HTN) or insomnia initially. In later stages, the patient may complain of nausea/vomiting, hematemesis, abdominal distension, epigastric pain, weight loss, jaundice, or other symptoms or signs suggestive of liver dysfunction. They may be asymptomatic early on.

On exam, they may exhibit signs of cerebellar dysfunction, such as ataxia or difficulty with fine motor skills. They may exhibit slurred speech, tachycardia, memory impairment, nystagmus, disinhibited behavior, or hypotension. They may present with tremors, confusion/mental status changes, asterixis, ruddy palms, jaundice, ascites, or other signs of advanced liver disease. There may also be spider angiomata, hepatomegaly/splenomegaly (early; liver becomes cirrhotic and shrunken in advanced disease). They may develop bleeding disorders, anemia, gastritis/ulcers, or pancreatitis as complications of the alcohol use. Labs will reveal anemia, thrombocytopenia, coagulopathy, hyponatremia, hyperammonemia, elevated ammonia levels, or decreased B12/folate levels as the advanced liver disease develops.

Evaluation

Evaluation should include questions about alcohol use, specifically how often and how much. A CAGE questionnaire as described above should be used, as well as the screening questions for alcohol use disorder that are displayed in the image below. The practitioner should elicit a family history regarding alcohol and other substance use disorders, as well as a family and personal history of any psychiatric disorders. The patient should be screened for any medical or behavioral complications of alcohol abuse, such as macrocytic anemia, elevated liver enzymes, coagulopathies, pancreatitis, frequent falls, job loss, relationship issues, or aberrant behaviors such as risky sexual behavior or impulsiveness.[8][9]

Medical Management

Some treatment foci that have demonstrated promise include evidence-based motivational interviewing. This particular approach helps the patients explore the reasons behind their ambivalence with respect to changing their behavior or alcohol cessation to change their substance abuse-related behaviors with a personalized assessment of risks and needs. Other therapies include cognitive behavior therapy, 24-hour residential facilities that aim to treat medical as well as psychiatric complications or comorbidities associated with the alcohol use and process of cessation. There are also multiple programs, such as Alcoholics Anonymous or other 12-step programs that focus on group support/mentors that can provide a source of assistance with the maintenance of abstinence. Many patients have lapses during their lifetime and will require initiation of differing intensities of therapy throughout their lifetime.[10][11]

Nursing Management

Screen patients using the AUDIT tool
Educate patients about harms of alcohol
Encourage AA
Refer patients to a mental health counselor

When To Seek Help

Sudden mood changes
Unresponsive
Confused, aggressive
Unstable vital signs

Outcome Identification

Abstains from alcohol
Eating a healthy diet

Monitoring

Observe mood
Check vital signs
Monitor ins and outs
Assess mental status

Coordination of Care

Alcohol abuse disorder is very common in the US. Unfortunately, most people never come to medical attention until they have a medical problem or get involved with the legal system. The repercussions of alcoholism go way beyond just addiction; the disorder can create havoc in the lives of the family, friends and lead to difficulties in interpersonal and professional relationships. Alcoholics never seek help on their own. All healthcare workers have a responsibility to watch out for alcoholics and make appropriate referrals. The prognosis for most alcoholics is guarded; with less than 20-30% discontinuing drinking. Unfortunately, in many instances some of the organ damage is often irreversible. The key is to educate the patient and the family about the destruction that alcohol can cause. Referral to alcoholics anonymous is recommended, but data indicate that compliance is often low. [1][8](Level V)

Health Teaching and Health Promotion

Eat a healthy diet and include fruits and vegetables

Attend AA

Follow up with a mental health counselor

Discharge Planning

Healthy diet

Attend AA

Follow up with a clinician

Seek help

Pearls and Other issues

Complications of alcohol use disorders can be far-reaching and can impact a patient's socioeconomic status, mental health, interpersonal relationships, employment, and physical well-being.

Early intervention and repeated non-malignant discussions between the patient and provider are important.

The patient's successes should be noted and resources for continued efforts offered at each visit.

Discussion regarding barriers to the patient seeking cessation or assistance should occur to find new ways to approach the alcohol use disorder (AUD) in the hope of improving successful cessation of the behaviors.

(Click Image to Enlarge)

DSM 5 Criteria for Alcohol Use Disorder
Contributed by Sara M Nehring

Details

References

[1]

Patigny P, Zdanowicz N, Lepiece B. How should psychiatrists and general physician communicate to increase patients' perception of continuity of care after their hospitalization for alcohol withdrawal? Psychiatria Danubina. 2018 Nov:30(Suppl 7):409-411 [PubMed PMID: 30439814]

[2]

Marel C, Sunderland M, Mills KL, Slade T, Teesson M, Chapman C. Conditional probabilities of substance use disorders and associated risk factors: Progression from first use to use disorder on alcohol, cannabis, stimulants, sedatives and opioids. Drug and alcohol dependence. 2019 Jan 1:194():136-142. doi: 10.1016/j.drugalcdep.2018.10.010. Epub 2018 Nov 3 [PubMed PMID: 30439610]

[3]

Jerlhag E. Gut-brain axis and addictive disorders: A review with focus on alcohol and drugs of abuse. Pharmacology & therapeutics. 2019 Apr:196():1-14. doi: 10.1016/j.pharmthera.2018.11.005. Epub 2018 Nov 12 [PubMed PMID: 30439457]

[4]

Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Science advances. 2019 Sep:5(9):eaax4043. doi: 10.1126/sciadv.aax4043. Epub 2019 Sep 25 [PubMed PMID: 31579824]

[5]

Tuithof M, Ten Have M, van den Brink W, Vollebergh W, de Graaf R. Treatment Seeking for Alcohol Use Disorders: Treatment Gap or Adequate Self-Selection? European addiction research. 2016:22(5):277-85. doi: 10.1159/000446822. Epub 2016 Jun 9 [PubMed PMID: 27287873]

[6]

Archibald L, Brunette MF, Wallin DJ, Green AI. Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder. Alcohol research : current reviews. 2019:40(1):. pii: arcr.v40.1.06. doi: 10.35946/arcr.v40.1.06. Epub 2019 Dec 20 [PubMed PMID: 31886105]

[7]

McHugh RK, Weiss RD. Alcohol Use Disorder and Depressive Disorders. Alcohol research : current reviews. 2019 Oct 21:40(1):. pii: arcr.v40.1.01. doi: 10.35946/arcr.v40.1.01. Epub 2019 Jan 1 [PubMed PMID: 31649834]

[8]

Pavón FJ, Serrano A, Stouffer DG, Polis I, Roberto M, Cravatt BF, Martin-Fardon R, Rodríguez de Fonseca F, Parsons LH. Ethanol-induced alterations in endocannabinoids and relevant neurotransmitters in the nucleus accumbens of fatty acid amide hydrolase knockout mice. Addiction biology. 2019 Nov:24(6):1204-1215. doi: 10.1111/adb.12695. Epub 2018 Nov 13 [PubMed PMID: 30421483]

[9]

Helle AC, Watts AL, Trull TJ, Sher KJ. Alcohol Use Disorder and Antisocial and Borderline Personality Disorders. Alcohol research : current reviews. 2019:40(1):. pii: arcr.v40.1.05. doi: 10.35946/arcr.v40.1.05. Epub 2019 Dec 30 [PubMed PMID: 31886107]

[10]

Edenberg HJ, McClintick JN. Alcohol Dehydrogenases, Aldehyde Dehydrogenases, and Alcohol Use Disorders: A Critical Review. Alcoholism, clinical and experimental research. 2018 Dec:42(12):2281-2297. doi: 10.1111/acer.13904. Epub 2018 Nov 11 [PubMed PMID: 30320893]

[11]

Egervari G, Siciliano CA, Whiteley EL, Ron D. Alcohol and the brain: from genes to circuits. Trends in neurosciences. 2021 Dec:44(12):1004-1015. doi: 10.1016/j.tins.2021.09.006. Epub 2021 Oct 23 [PubMed PMID: 34702580]

[12]

Li D, Sulovari A, Cheng C, Zhao H, Kranzler HR, Gelernter J. Association of gamma-aminobutyric acid A receptor α2 gene (GABRA2) with alcohol use disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2014 Mar:39(4):907-18. doi: 10.1038/npp.2013.291. Epub 2013 Oct 18 [PubMed PMID: 24136292]

[13]

Lovallo WR, Cohoon AJ, Sorocco KH, Vincent AS, Acheson A, Hodgkinson CA, Goldman D. Early-Life Adversity and Blunted Stress Reactivity as Predictors of Alcohol and Drug use in Persons With COMT (rs4680) Val158Met Genotypes. Alcoholism, clinical and experimental research. 2019 Jul:43(7):1519-1527. doi: 10.1111/acer.14079. Epub 2019 May 31 [PubMed PMID: 31150143]

[14]

Wang F, Simen A, Arias A, Lu QW, Zhang H. A large-scale meta-analysis of the association between the ANKK1/DRD2 Taq1A polymorphism and alcohol dependence. Human genetics. 2013 Mar:132(3):347-58. doi: 10.1007/s00439-012-1251-6. Epub 2012 Dec 1 [PubMed PMID: 23203481]

[15]

Zuo L, Lu L, Tan Y, Pan X, Cai Y, Wang X, Hong J, Zhong C, Wang F, Zhang XY, Vanderlinden LA, Tabakoff B, Luo X. Genome-wide association discoveries of alcohol dependence. The American journal on addictions. 2014 Nov-Dec:23(6):526-39. doi: 10.1111/j.1521-0391.2014.12147.x. Epub [PubMed PMID: 25278008]

[16]

Witkiewitz K, Kranzler HR, Hallgren KA, O'Malley SS, Falk DE, Litten RZ, Hasin DS, Mann KF, Anton RF. Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. Alcoholism, clinical and experimental research. 2018 Dec:42(12):2453-2465. doi: 10.1111/acer.13897. Epub 2018 Nov 5 [PubMed PMID: 30395350]

[17]

Degenhardt L, Bharat C, Bruno R, Glantz MD, Sampson NA, Lago L, Aguilar-Gaxiola S, Alonso J, Andrade LH, Bunting B, Caldas-de-Almeida JM, Cia AH, Gureje O, Karam EG, Khalaf M, McGrath JJ, Moskalewicz J, Lee S, Mneimneh Z, Navarro-Mateu F, Sasu CC, Scott K, Torres Y, Poznyak V, Chatterji S, Kessler RC, WHO World Mental Health Survey Collaborators. Concordance between the diagnostic guidelines for alcohol and cannabis use disorders in the draft ICD-11 and other classification systems: analysis of data from the WHO's World Mental Health Surveys. Addiction (Abingdon, England). 2019 Mar:114(3):534-552. doi: 10.1111/add.14482. Epub 2018 Dec 9 [PubMed PMID: 30370636]

[18]

Mannes ZL, Hearn LE, Zhou Z, Janelle JW, Cook RL, Ennis N. The association between symptoms of generalized anxiety disorder and appointment adherence, overnight hospitalization, and emergency department/urgent care visits among adults living with HIV enrolled in care. Journal of behavioral medicine. 2019 Apr:42(2):330-341. doi: 10.1007/s10865-018-9988-6. Epub 2018 Nov 1 [PubMed PMID: 30387009]

[19]

Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. The lancet. Psychiatry. 2016 Aug:3(8):760-773. doi: 10.1016/S2215-0366(16)00104-8. Epub [PubMed PMID: 27475769]

[20]

Flores-Bonilla A, Richardson HN. Sex Differences in the Neurobiology of Alcohol Use Disorder. Alcohol research : current reviews. 2020:40(2):04. doi: 10.35946/arcr.v40.2.04. Epub 2020 Oct 8 [PubMed PMID: 33042719]

[21]

Le Daré B, Lagente V, Gicquel T. Ethanol and its metabolites: update on toxicity, benefits, and focus on immunomodulatory effects. Drug metabolism reviews. 2019 Nov:51(4):545-561. doi: 10.1080/03602532.2019.1679169. Epub 2019 Oct 24 [PubMed PMID: 31646907]

[22]

Cederbaum AI. Alcohol metabolism. Clinics in liver disease. 2012 Nov:16(4):667-85. doi: 10.1016/j.cld.2012.08.002. Epub [PubMed PMID: 23101976]

[23]

Lu Y, Cederbaum AI. Cytochrome P450s and Alcoholic Liver Disease. Current pharmaceutical design. 2018:24(14):1502-1517. doi: 10.2174/1381612824666180410091511. Epub [PubMed PMID: 29637855]

[24]

Kwo PY, Ramchandani VA, O'Connor S, Amann D, Carr LG, Sandrasegaran K, Kopecky KK, Li TK. Gender differences in alcohol metabolism: relationship to liver volume and effect of adjusting for body mass. Gastroenterology. 1998 Dec:115(6):1552-7 [PubMed PMID: 9834284]

[25]

Ramchandani VA, Kwo PY, Li TK. Effect of food and food composition on alcohol elimination rates in healthy men and women. Journal of clinical pharmacology. 2001 Dec:41(12):1345-50 [PubMed PMID: 11762562]

[26]

US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Nov 13:320(18):1899-1909. doi: 10.1001/jama.2018.16789. Epub [PubMed PMID: 30422199]

[27]

Hellberg SN, Russell TI, Robinson MJF. Cued for risk: Evidence for an incentive sensitization framework to explain the interplay between stress and anxiety, substance abuse, and reward uncertainty in disordered gambling behavior. Cognitive, affective & behavioral neuroscience. 2019 Jun:19(3):737-758. doi: 10.3758/s13415-018-00662-3. Epub [PubMed PMID: 30357661]

[28]

Helander A, Wielders J, Anton R, Arndt T, Bianchi V, Deenmamode J, Jeppsson JO, Whitfield JB, Weykamp C, Schellenberg F, International Federation of Clinical Chemistry and Laboratory Medicine Working Group on Standardisation of Carbohydrate-Deficient Transferrin (IFCC WG-CDT). Standardisation and use of the alcohol biomarker carbohydrate-deficient transferrin (CDT). Clinica chimica acta; international journal of clinical chemistry. 2016 Aug 1:459():19-24. doi: 10.1016/j.cca.2016.05.016. Epub 2016 May 21 [PubMed PMID: 27221205]

[29]

Gerbase FE, Tegner M, Krutzmann ME, Muller VV, Alff JA, da Silva VB, Sagrilo OP, Linden R, Antunes MV. Blood phosphatidyl ethanol levels as a tool to detect alcohol misuse in trauma patients. Clinical toxicology (Philadelphia, Pa.). 2021 May:59(5):418-425. doi: 10.1080/15563650.2020.1822531. Epub 2020 Oct 6 [PubMed PMID: 33021410]

[30]

Lundahl B, Moleni T, Burke BL, Butters R, Tollefson D, Butler C, Rollnick S. Motivational interviewing in medical care settings: a systematic review and meta-analysis of randomized controlled trials. Patient education and counseling. 2013 Nov:93(2):157-68. doi: 10.1016/j.pec.2013.07.012. Epub 2013 Aug 1 [PubMed PMID: 24001658]

[31]

VanBuskirk KA, Wetherell JL. Motivational interviewing with primary care populations: a systematic review and meta-analysis. Journal of behavioral medicine. 2014 Aug:37(4):768-80. doi: 10.1007/s10865-013-9527-4. Epub 2013 Aug 11 [PubMed PMID: 23934180]

[32]

Smedslund G, Berg RC, Hammerstrøm KT, Steiro A, Leiknes KA, Dahl HM, Karlsen K. Motivational interviewing for substance abuse. The Cochrane database of systematic reviews. 2011 May 11:2011(5):CD008063. doi: 10.1002/14651858.CD008063.pub2. Epub 2011 May 11 [PubMed PMID: 21563163]

[33]

Carroll KM, Kiluk BD. Cognitive behavioral interventions for alcohol and drug use disorders: Through the stage model and back again. Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors. 2017 Dec:31(8):847-861. doi: 10.1037/adb0000311. Epub 2017 Aug 31 [PubMed PMID: 28857574]

[34]

Coriale G, Fiorentino D, De Rosa F, Solombrino S, Scalese B, Ciccarelli R, Attilia F, Vitali M, Musetti A, Fiore M, Ceccanti M, Interdisciplinary Study Group CRARL - SITAC - SIPaD - SITD - SIPDip. Treatment of alcohol use disorder from a psychological point of view. Rivista di psichiatria. 2018 May-Jun:53(3):141-148. doi: 10.1708/2925.29416. Epub [PubMed PMID: 29912216]

[35]

Kranzler HR, Soyka M. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review. JAMA. 2018 Aug 28:320(8):815-824. doi: 10.1001/jama.2018.11406. Epub [PubMed PMID: 30167705]

[36]

Godderis L, Boonen E, Cabrera Martimbianco AL, Delvaux E, Ivanov ID, Lambrechts MC, Latorraca COC, Leppink N, Pega F, Prüss-Ustün AM, Riera R, Ujita Y, Pachito DV. WHO/ILO work-related burden of disease and injury: Protocol for systematic reviews of exposure to long working hours and of the effect of exposure to long working hours on alcohol consumption and alcohol use disorders. Environment international. 2018 Nov:120():22-33. doi: 10.1016/j.envint.2018.07.025. Epub 2018 Jul 25 [PubMed PMID: 30055358]

[37]

Patel AK, Balasanova AA. Treatment of Alcohol Use Disorder. JAMA. 2021 Feb 9:325(6):596. doi: 10.1001/jama.2020.2012. Epub [PubMed PMID: 33560323]

[38]

Aletraris L, Bond Edmond M, Roman PM. Adoption of injectable naltrexone in U.S. substance use disorder treatment programs. Journal of studies on alcohol and drugs. 2015 Jan:76(1):143-51 [PubMed PMID: 25486403]

[39]

Singh D, Saadabadi A. Naltrexone. StatPearls. 2023 Jan:(): [PubMed PMID: 30521232]

[40]

Pettinati HM, Silverman BL, Battisti JJ, Forman R, Schweizer E, Gastfriend DR. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcoholism, clinical and experimental research. 2011 Oct:35(10):1804-11. doi: 10.1111/j.1530-0277.2011.01524.x. Epub 2011 May 16 [PubMed PMID: 21575016]

[41]

O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. Journal of clinical psychopharmacology. 2007 Oct:27(5):507-12 [PubMed PMID: 17873686]

[42]

Lee JD, Grossman E, Huben L, Manseau M, McNeely J, Rotrosen J, Stevens D, Gourevitch MN. Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months. Journal of substance abuse treatment. 2012 Dec:43(4):458-62. doi: 10.1016/j.jsat.2012.08.012. Epub 2012 Sep 15 [PubMed PMID: 22985676]

[43]

Weinstein A, Feldtkeller B, Feeney A, Lingford-Hughes A, Nutt D. A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patients. Addiction biology. 2003 Jun:8(2):229-32 [PubMed PMID: 12850782]

[44]

Pierrefiche O, Daoust M, Naassila M. Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network. Neuropharmacology. 2004 Jul:47(1):35-45 [PubMed PMID: 15165832]

[45]

Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. The Cochrane database of systematic reviews. 2010 Sep 8:(9):CD004332. doi: 10.1002/14651858.CD004332.pub2. Epub 2010 Sep 8 [PubMed PMID: 20824837]

[46]

Shen WW. Anticraving therapy for alcohol use disorder: A clinical review. Neuropsychopharmacology reports. 2018 Sep:38(3):105-116. doi: 10.1002/npr2.12028. Epub [PubMed PMID: 30175522]

[47]

Roberto M, Cruz MT, Gilpin NW, Sabino V, Schweitzer P, Bajo M, Cottone P, Madamba SG, Stouffer DG, Zorrilla EP, Koob GF, Siggins GR, Parsons LH. Corticotropin releasing factor-induced amygdala gamma-aminobutyric Acid release plays a key role in alcohol dependence. Biological psychiatry. 2010 May 1:67(9):831-9. doi: 10.1016/j.biopsych.2009.11.007. Epub 2010 Jan 8 [PubMed PMID: 20060104]

[48]

Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert opinion on investigational drugs. 2018 Jan:27(1):113-124. doi: 10.1080/13543784.2018.1417383. Epub 2017 Dec 23 [PubMed PMID: 29241365]

[49]

Manhapra A, Chakraborty A, Arias AJ. Topiramate Pharmacotherapy for Alcohol Use Disorder and Other Addictions: A Narrative Review. Journal of addiction medicine. 2019 Jan/Feb:13(1):7-22. doi: 10.1097/ADM.0000000000000443. Epub [PubMed PMID: 30096077]

[50]

Reus VI, Fochtmann LJ, Bukstein O, Eyler AE, Hilty DM, Horvitz-Lennon M, Mahoney J, Pasic J, Weaver M, Wills CD, McIntyre J, Kidd J, Yager J, Hong SH. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Focus (American Psychiatric Publishing). 2019 Apr:17(2):158-162. doi: 10.1176/appi.focus.17205. Epub 2019 Apr 10 [PubMed PMID: 32021585]